Skip to content
Stack & save: 10% off 3+ vials, 15% off 5+ · Free shipping over $250
Cart 0
Compound Files

PT-141 Research Guide: Bremelanotide and Melanocortin Signaling

Understand Hero PT-141, its relationship to bremelanotide research, the boundary around approved preparations, and the documentation needed for laboratory studies.

Hero Peptides Research TeamUpdated Nov 20265 min read

Quick facts

Catalog name PT-141
Related compound name Bremelanotide
Research family Melanocortin receptor agonists
Exported size 10 mg
Evidence distinction Approved Vyleesi and a separate research sample are different products
Hero product PT-141

PT-141 is a research name associated with bremelanotide, a melanocortin receptor agonist. Its literature spans pharmacology and clinical research, but the existence of an approved bremelanotide medicine does not make every sample carrying the related name an equivalent product.

Hero’s supplied export lists PT-141 with a 10 mg variant. This guide explains the naming, the receptor-research context, and how to read clinical evidence while keeping the identity and properties of Hero’s separately supplied material clear.

PT-141. View catalog product

Origin story: a research name and a medicine name

Bremelanotide is the active ingredient named in the approved medicine Vyleesi. Its prescribing information identifies it as a melanocortin receptor agonist and records initial U.S. approval in 2019. That is a statement about a specified finished medicine (FDA, 2026).

PT-141 is the related name used in Hero’s catalog. For a laboratory materials section, retain that catalog identity and verify the precise sequence, chemical form, and terminal structure in the lot documentation. A naming relationship does not establish that every supplied preparation is identical.

The Melanotan 2 guide covers a distinct related peptide. Similar research histories should not lead to shared specifications or evidence being transferred between compounds without checking the structure tested.

How the receptor research is framed

Melanocortin receptors form a family. A pharmacological description should specify which targets were studied and how activity was measured. A family-level label cannot independently identify the receptor contribution to a later whole-organism endpoint.

The current Vyleesi label describes melanocortin activity while also identifying limits to the established clinical mechanism. That is a useful reminder that measured receptor pharmacology and a complete explanation of a clinical response are separate questions (FDA, 2026).

For an experimental comparison, distinguish binding from functional signaling. Then identify the receptor system, concentration range, exposure, and comparator. A single concentration or a response in a different model cannot describe the entire pharmacological profile.

A useful research record also separates nominal concentration from measured sample properties. Knowing how much material was calculated into a solution does not independently verify its chemical identity or the response it will produce.

Key evidence: what the clinical trials actually addressed

Source Preparation or setting Useful information Boundary
RECONNECT publication, 2019 Two randomized clinical trials Clinical endpoints and adverse events in a defined population Not a trial of Hero’s research material
Vyleesi prescribing information A specified approved medicine Authorized indication, pharmacology, and safety information Not approval for a separate vial
Hero lot documentation The actual laboratory sample Stated identity and reported analytical results Not a clinical effectiveness study

The RECONNECT studies were randomized, double-blind, placebo-controlled trials in premenopausal women with a defined hypoactive sexual desire disorder diagnosis. The publication reports clinical endpoints and adverse events within that study population and preparation (Kingsberg et al., 2019).

Those results should not become a general claim about sexual performance or an outcome for all populations. The diagnostic criteria, comparator, formulation, and endpoint definitions are part of the evidence. Removing them changes the claim being made.

Trial evidence is also different from direct material characterization. A published clinical result cannot establish the identity, amount, purity, or biological potency of the sample later used in a laboratory. Keep those questions attached to the actual lot and experiment.

Weak spots: approval belongs to the specified product

As of November 17, 2026, Vyleesi is an approved bremelanotide medicine with a restricted indication and stated limitations. Its labeling does not establish approval or interchangeability for Hero PT-141. This guide does not supply administration instructions or a personal-use protocol (FDA, 2026).

The clinical publication reports nausea and other adverse events. Its results should be read together with its safety information, rather than treated as evidence of an uncomplicated response to any product bearing a related name (Kingsberg et al., 2019).

Exact identity is another limitation. A general description such as melanocortin peptide does not identify sequence, stereochemistry, terminal chemistry, or counterion. Those details can matter to a method and should be verified where relevant.

Likewise, a favorable analytical purity result is not an independent receptor-potency measurement. If a functional response is essential to the experiment, define the assay and reference controls needed to evaluate that response.

Handling PT-141 in the lab

The exported 10 mg format identifies nominal material mass. Preparation conditions must follow the actual lot documentation and the validated requirements of the intended assay. A finished medicine’s delivery instructions are not a laboratory preparation method for a separate research sample.

For arithmetic only, nominal 10 mg at a final solution volume of 2 mL gives 5 mg/mL. At a final volume of 4 mL in a suitable vessel, it gives 2.5 mg/mL. These examples do not establish solvent compatibility, vial capacity, or a biological test concentration.

A later dilution should retain stock concentration, transferred volume, and final volume in the record. If two materials are compared at equal molarity, confirm the appropriate molecular-weight basis for each. Equal masses alone do not establish equal molecule counts.

The calculator and mass-conversion guide support the arithmetic. The testing explainer describes the distinction between identity and chromatographic purity.

Use the COA guide to examine the matching lot report. Keep product ID, material specification, lot, preparation date, solvent, and dilution history together. Record missing properties explicitly instead of filling them from an unrelated supplier’s listing.

PT-141 FAQ

Why is PT-141 discussed alongside bremelanotide?

The names are connected in the compound’s research history. The exact identity and preparation of a supplied sample still need documentation.

Is Hero PT-141 the same product as Vyleesi?

No equivalence is established here. Vyleesi is a specified finished medicine, while Hero’s entry describes separately supplied research material.

Do clinical trial results establish a new lot’s potency?

No. Trial outcomes and a sample’s analytical or functional properties are separate evidence questions.

What is Hero PT-141?

It is the PT-141 product in Hero’s supplied export, listed with a 10 mg variant. Current stock and exact lot properties were not independently verified.

PT-141. View catalog product

References

  1. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. Source.
  2. U.S. Food and Drug Administration. Vyleesi (bremelanotide), prescribing information. 2026. Source.
For laboratory research use only. Not for human or veterinary use. This article is educational and is not medical advice.

Read next

Add 3 vials for 10% off
Build my stack